IgE-mediated anaphylactic reactions to neuromuscular blocking agents: can they be prevented?
Florvaag
E
E
Department of Clinical Immunology, Karolinska University Hospital, Solna, L2:04, S-171 76, Stockholm, Sweden. s.g.o.johansson@ki.se
Johansson
S G O
SG
D000700:Analgesics / Q000009:adverse effects / Q000276:immunology; D000707:Anaphylaxis / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control; D000758:Anesthesia / Q000009:adverse effects; D000996:Antitussive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D003061:Codeine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000276:immunology; D004342:Drug Hypersensitivity / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control; D004363:Drug Utilization; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood / Q000276:immunology*; D009025:Morpholines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D009467:Neuromuscular Depolarizing Agents / Q000009:adverse effects* / Q000276:immunology; D009664:Norway / Q000453:epidemiology; D013390:Succinylcholine / Q000009:adverse effects / Q000276:immunology; D013548:Sweden / Q000453:epidemiology
D000700:Analgesics; D000996:Antitussive Agents; D009025:Morpholines; D009467:Neuromuscular Depolarizing Agents; D007073:Immunoglobulin E; D013390:Succinylcholine; C008872:pholcodine; D003061:Codeine